Primary Sclerosing Cholangitis Market Report and Forecast 2025-2034
Description
The primary sclerosing cholangitis market size in the 7 major markets was valued at USD 151.07 Million in 2024, driven by the rising technical advancements in drug development. The market is expected to grow at a CAGR of 7.60% during the forecast period of 2025-2034, with the values likely to reach USD 314.27 Million by 2034.
Primary Sclerosing Cholangitis: Introduction
Primary sclerosis cholangitis is a chronic liver condition where the bile ducts get inflamed, scarred, and eventually becomes narrow and blocked. The disease progresses slowly and eventually leads to liver failure. Common symptoms include itchy area, abdomen pain, jaundice, diarrhea or fatigue and fever. It is caused by an immune system reaction to a toxin or infection. Liver function blood tests, bile duct MRIs and CT scans are used to diagnose the condition in patients.
Primary Sclerosing Cholangitis Market Analysis
The primary sclerosing cholangitis market demand is poised to rise with increasing frequency of drug development demonstrating positive results in clinical trials. In June 2023, Chemomab Therapeutics Ltd. presented positive data supporting CM-101, a CCL24-neutralizing antibody, as a driver of disease pathology in detecting primary sclerosing cholangitis. In addition, Galmed Pharmaceuticals Ltd. also launched a clinical program to evaluate its lead compound, Aramchol meglumine, for the treatment of PSC. This also indicates the rising trend of pharmaceutical companies taking part in expanding their product portfolios.
As a part of further investigation, researchers have also been working on developing PSC-IBD (inflammatory bowel disease) combined medications. This is because the pathogenesis and treatment for both is similar. Potential candidate drugs, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis, have been developed for both. Bile acids modulators such as Obeticholic acid, Cilofexor and inflammation modulators like Cenicriviroc, Vedolizumab, along with statins, are some key areas of investigation. The rising investment and research and development in the market is anticipated to aid the market growth further.
The rising prevalence of minimally invasive procedures, owing to benefits like faster recovery and lesser complications, is expected to boost the primary sclerosing cholangitis market growth in the forecast period.
Primary Sclerosing Cholangitis Market Segmentation
“Primary Sclerosing Cholangitis Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Owing to the rising primary sclerosing cholangitis market demand, the United States has made significant efforts to offer a diverse of effective treatment alternative to the patients. The presence of prominent pharmaceutical and healthcare companies, as well as research institutions has fuelled the market growth.
To combat the increasing liver associated diseases, countries like Japan, China, and India have been working on improving the medical and research infrastructure of the region. The government of India has launched a ‘Illness to Wellness’ campaign in August 2023. This national awareness program promoted healthy living with balanced diet, along with good eating habits. Such programs are expected to contribute significantly to the rising primary sclerosing cholangitis market share in the coming years.
Europe is another significant player in the market with a well-developed research infrastructure that aids in development and testing of new technologies and drugs. The World Health Organization launched “One life, one liver” to boost awareness on liver health. Such initiatives and campaigns are also anticipated to boost the market value in the forecast period as well.
Primary Sclerosing Cholangitis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Primary Sclerosing Cholangitis: Introduction
Primary sclerosis cholangitis is a chronic liver condition where the bile ducts get inflamed, scarred, and eventually becomes narrow and blocked. The disease progresses slowly and eventually leads to liver failure. Common symptoms include itchy area, abdomen pain, jaundice, diarrhea or fatigue and fever. It is caused by an immune system reaction to a toxin or infection. Liver function blood tests, bile duct MRIs and CT scans are used to diagnose the condition in patients.
Primary Sclerosing Cholangitis Market Analysis
The primary sclerosing cholangitis market demand is poised to rise with increasing frequency of drug development demonstrating positive results in clinical trials. In June 2023, Chemomab Therapeutics Ltd. presented positive data supporting CM-101, a CCL24-neutralizing antibody, as a driver of disease pathology in detecting primary sclerosing cholangitis. In addition, Galmed Pharmaceuticals Ltd. also launched a clinical program to evaluate its lead compound, Aramchol meglumine, for the treatment of PSC. This also indicates the rising trend of pharmaceutical companies taking part in expanding their product portfolios.
As a part of further investigation, researchers have also been working on developing PSC-IBD (inflammatory bowel disease) combined medications. This is because the pathogenesis and treatment for both is similar. Potential candidate drugs, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis, have been developed for both. Bile acids modulators such as Obeticholic acid, Cilofexor and inflammation modulators like Cenicriviroc, Vedolizumab, along with statins, are some key areas of investigation. The rising investment and research and development in the market is anticipated to aid the market growth further.
The rising prevalence of minimally invasive procedures, owing to benefits like faster recovery and lesser complications, is expected to boost the primary sclerosing cholangitis market growth in the forecast period.
Primary Sclerosing Cholangitis Market Segmentation
“Primary Sclerosing Cholangitis Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Classic PSC
- Small-duct PSC
- PSC Associated with Autoimmune Hepatitis
- Ursodeoxycholic Acid
- Obeticholic Acid
- Methotrexate
- Corticosteroids
- Others
- Antihistamines
- Cholestyramine
- Antibacterials
- Opioid Antagonists
- Colestipol
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
Owing to the rising primary sclerosing cholangitis market demand, the United States has made significant efforts to offer a diverse of effective treatment alternative to the patients. The presence of prominent pharmaceutical and healthcare companies, as well as research institutions has fuelled the market growth.
To combat the increasing liver associated diseases, countries like Japan, China, and India have been working on improving the medical and research infrastructure of the region. The government of India has launched a ‘Illness to Wellness’ campaign in August 2023. This national awareness program promoted healthy living with balanced diet, along with good eating habits. Such programs are expected to contribute significantly to the rising primary sclerosing cholangitis market share in the coming years.
Europe is another significant player in the market with a well-developed research infrastructure that aids in development and testing of new technologies and drugs. The World Health Organization launched “One life, one liver” to boost awareness on liver health. Such initiatives and campaigns are also anticipated to boost the market value in the forecast period as well.
Primary Sclerosing Cholangitis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Allergan
- Glenmark Pharmaceutical
- Merck & Co
- Sanofi
- Novatris AG
- Baxter
- Pfizer Inc.
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd
- Abbott
- Mylan N.V.
- HighTide Inc.
- Sirnaomics
- Acorda Therapeutics
- NGM Biopharmaceuticals
- Sandoz International GmbH
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Primary Sclerosing Cholangitis Syndrome Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Primary Sclerosing Cholangitis Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 5.3.2 France Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 5.4 Japan Primary Sclerosing Cholangitis Epidemiology Forecast (2018-2034)
- 6 Primary Sclerosing Cholangitis Market Overview – 7MM
- 6.1 Primary Sclerosing Cholangitis Market Historical Value (2018-2024)
- 6.2 Primary Sclerosing Cholangitis Market Forecast Value (2025-2034)
- 7 Primary Sclerosing Cholangitis Market Landscape – 7MM
- 7.1 Primary Sclerosing Cholangitis Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Primary Sclerosing Cholangitis Product Landscape
- 7.2.1 Analysis by Diseases Type
- 7.2.2 Analysis by Treatments
- 7.2.3 Analysis by Route of Administration
- 8 Primary Sclerosing Cholangitis Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Primary Sclerosing Cholangitis Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Primary Sclerosing Cholangitis Market Segmentation – 7MM
- 11.1 Primary Sclerosing Cholangitis Market by Type
- 11.1.1 Market Overview
- 11.1.2 Classic PSC
- 11.1.3 Small-duct PSC
- 11.1.4 PSC Associated with Autoimmune Hepatitis
- 11.2 Primary Sclerosing Cholangitis Market by Treatment
- 11.2.1 Market Overview
- 11.2.2 Ursodeoxycholic Acid
- 11.2.3 Obeticholic Acid
- 11.2.4 Methotrexate
- 11.2.5 Corticosteroids
- 11.2.6 Others
- 11.3 Primary Sclerosing Cholangitis Market by Drug Class
- 11.3.1 Market Overview
- 11.3.2 Antihistamines
- 11.3.3 Cholestyramine
- 11.3.4 Antibacterials
- 11.3.5 Opioid Antagonists
- 11.3.6 Colestipol
- 11.3.7 Others
- 11.4 Primary Sclerosing Cholangitis Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Primary Sclerosing Cholangitis Market
- 12.1 Primary Sclerosing Cholangitis Market Historical Value (2018-2024)
- 12.2 Primary Sclerosing Cholangitis Market Forecast Value (2025-2034)
- 12.3 Primary Sclerosing Cholangitis Market by Disease Type
- 12.4 Primary Sclerosing Cholangitis Market by Treatment Type
- 13 EU-4 and United Kingdom Primary Sclerosing Cholangitis Market
- 13.1 Primary Sclerosing Cholangitis Market Historical Value (2018-2024)
- 13.2 Primary Sclerosing Cholangitis Market Forecast Value (2025-2034)
- 13.3 Germany Primary Sclerosing Cholangitis Market Overview
- 13.3.1 Primary Sclerosing Cholangitis Market by Disease Type
- 13.3.2 Primary Sclerosing Cholangitis Market by Treatment Type
- 13.4 France Primary Sclerosing Cholangitis Market Overview
- 13.4.1 Primary Sclerosing Cholangitis Market by Disease Type
- 13.4.2 Primary Sclerosing Cholangitis Market by Treatment Type
- 13.5 Italy Primary Sclerosing Cholangitis Market Overview
- 13.5.1 Primary Sclerosing Cholangitis Market by Disease Type
- 13.5.2 Primary Sclerosing Cholangitis Market by Treatment Type
- 13.6 Spain Primary Sclerosing Cholangitis Market Overview
- 13.6.1 Primary Sclerosing Cholangitis Market by Disease Type
- 13.6.2 Primary Sclerosing Cholangitis Market by Treatment Type
- 13.7 United Kingdom Primary Sclerosing Cholangitis Market Overview
- 13.7.1 Primary Sclerosing Cholangitis Market by Disease Type
- 13.7.2 Primary Sclerosing Cholangitis Market by Treatment Type
- 14 Japan Primary Sclerosing Cholangitis Market
- 14.1 Primary Sclerosing Cholangitis Market Historical Value (2018-2024)
- 14.2 Primary Sclerosing Cholangitis Market Forecast Value (2025-2034)
- 14.3 Primary Sclerosing Cholangitis Market by Disease Type
- 14.4 Primary Sclerosing Cholangitis Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Allergan
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Glenmark Pharmaceutical
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Merck & Co
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Sanofi
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Novatris AG
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Baxter
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 Pfizer Inc.
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Takeda Pharmaceutical
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 F. Hoffmann-La Roche Ltd
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 Abbott
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Mylan N.V.
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 HighTide Inc.
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Sirnaomics
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Acorda Therapeutics
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 NGM Biopharmaceuticals
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 20.16 Sandoz International GmbH
- 20.16.1 Financial Analysis
- 20.16.2 Product Portfolio
- 20.16.3 Demographic Reach and Achievements
- 20.16.4 Mergers and Acquisition
- 20.16.5 Certifications
- 21 Primary Sclerosing Cholangitis Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
